310859214-Oa
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Role of RNA Editing in Cancer Development and Metabolic Disorders
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2018 The oler of RNA editing in cancer development and metabolic disorders Che-Pei Kung Washington University School of Medicine in St. Louis Leonard B. Maggi Jr. Washington University School of Medicine in St. Louis Jason D. Weber Washington University School of Medicine in St. Louis Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Kung, Che-Pei; Maggi, Leonard B. Jr.; and Weber, Jason D., ,"The or le of RNA editing in cancer development and metabolic disorders." Frontiers in endocrinology.9,. 762. (2018). https://digitalcommons.wustl.edu/open_access_pubs/7400 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. REVIEW published: 18 December 2018 doi: 10.3389/fendo.2018.00762 The Role of RNA Editing in Cancer Development and Metabolic Disorders Che-Pei Kung 1,2*, Leonard B. Maggi Jr. 1,2 and Jason D. Weber 1,2,3* 1 ICCE Institute, Washington University School of Medicine, Saint Louis, MO, United States, 2 Division of Molecular Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, United States, 3 Siteman Cancer Center, Department of Cell Biology and Physiology, Washington University School of Medicine, Saint Louis, MO, United States Numerous human diseases arise from alterations of genetic information, most notably DNA mutations. Thought to be merely the intermediate between DNA and protein, changes in RNA sequence were an afterthought until the discovery of RNA editing 30 years ago. -
Mohammad Karbaschi Thesis
STRUCTURAL, PHYSIOLOGICAL AND MOLECULAR CHARACTERISATION OF THE AUSTRALIAN NATIVE RESURRECTION GRASS TRIPOGON LOLIIFORMIS (F.MUELL.) C.E.HUBB. DURING DEHYDRATION AND REHYDRATION Mohammad Reza Karbaschi Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy Centre for Tropical Crops and Biocommodities Science and Engineering Faculty Queensland University of Technology November 2015 Keywords Arabidopsis thaliana; Agrobacterium-mediated transformation; Anatomy; Anti-apoptotic proteins; BAG4; Escherichia coli; Bulliform cells; C4 photosynthesis; Cell wall folding; Cell membrane integrity; Chaperone-mediated autophagy; Chlorophyll fluorescence; Hsc70/Hsp70; Desiccation tolerance, Dehydration; Drought; Electrolyte leakage; Freehand sectioning; Homoiochlorophyllous; Leaf structure; Leaf folding; Reactive oxygen species (ROS); Resurrection plant; Morphology; Monocotyledon; Nicotiana benthamiana; Photosynthesis; Physiology; Plant tissue; Programed cell death (PCD); Propidium iodide staining; Protein microarray chip; Sclerenchymatous tissue; Stress; Structure; Tripogon loliiformis; Ubiquitin; Vacuole fragmentation; Kranz anatomy; XyMS+; Structural, physiological and molecular characterisation of the Australian native resurrection grass Tripogon loliiformis (F.Muell.) C.E.Hubb. during dehydration and rehydration i Abstract Plants, as sessile organisms must continually adapt to environmental changes. Water deficit is one of the major environmental stresses that affects plants. While most plants can tolerate moderate dehydration -
Supplementary Table 2 Supplementary Table 1
Supplementary table 1 Rai/ Binet IGHV Cytogenetic Relative viability Fludarabine- Sex Outcome CD38 (%) IGHV gene ZAP70 (%) Treatment (s) Stage identity (%) abnormalities* increase refractory 1 M 0/A Progressive 14,90 IGHV3-64*05 99,65 28,20 Del17p 18.0% 62,58322819 FCR n.a. 2 F 0/A Progressive 78,77 IGHV3-48*03 100,00 51,90 Del17p 24.8% 77,88052021 FCR n.a. 3 M 0/A Progressive 29,81 IGHV4-b*01 100,00 9,10 Del17p 12.0% 36,48 Len, Chl n.a. 4 M 1/A Stable 97,04 IGHV3-21*01 97,22 18,11 Normal 85,4191657 n.a. n.a. Chl+O, PCR, 5 F 0/A Progressive 87,00 IGHV4-39*07 100,00 43,20 Del13q 68.3% 35,23314039 n.a. HDMP+R 6 M 0/A Progressive 1,81 IGHV3-43*01 100,00 20,90 Del13q 77.7% 57,52490626 Chl n.a. Chl, FR, R-CHOP, 7 M 0/A Progressive 97,80 IGHV1-3*01 100,00 9,80 Del17p 88.5% 48,57389901 n.a. HDMP+R 8 F 2/B Progressive 69,07 IGHV5-a*03 100,00 16,50 Del17p 77.2% 107,9656878 FCR, BA No R-CHOP, FCR, 9 M 1/A Progressive 2,13 IGHV3-23*01 97,22 29,80 Del11q 16.3% 134,5866919 Yes Flavopiridol, BA 10 M 2/A Progressive 0,36 IGHV3-30*02 92,01 0,38 Del13q 81.9% 78,91844953 Unknown n.a. 11 M 2/B Progressive 15,17 IGHV3-20*01 100,00 13,20 Del11q 95.3% 75,52880995 FCR, R-CHOP, BR No 12 M 0/A Stable 0,14 IGHV3-30*02 90,62 7,40 Del13q 13.0% 13,0939004 n.a. -
Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement. -
Open Data for Differential Network Analysis in Glioma
International Journal of Molecular Sciences Article Open Data for Differential Network Analysis in Glioma , Claire Jean-Quartier * y , Fleur Jeanquartier y and Andreas Holzinger Holzinger Group HCI-KDD, Institute for Medical Informatics, Statistics and Documentation, Medical University Graz, Auenbruggerplatz 2/V, 8036 Graz, Austria; [email protected] (F.J.); [email protected] (A.H.) * Correspondence: [email protected] These authors contributed equally to this work. y Received: 27 October 2019; Accepted: 3 January 2020; Published: 15 January 2020 Abstract: The complexity of cancer diseases demands bioinformatic techniques and translational research based on big data and personalized medicine. Open data enables researchers to accelerate cancer studies, save resources and foster collaboration. Several tools and programming approaches are available for analyzing data, including annotation, clustering, comparison and extrapolation, merging, enrichment, functional association and statistics. We exploit openly available data via cancer gene expression analysis, we apply refinement as well as enrichment analysis via gene ontology and conclude with graph-based visualization of involved protein interaction networks as a basis for signaling. The different databases allowed for the construction of huge networks or specified ones consisting of high-confidence interactions only. Several genes associated to glioma were isolated via a network analysis from top hub nodes as well as from an outlier analysis. The latter approach highlights a mitogen-activated protein kinase next to a member of histondeacetylases and a protein phosphatase as genes uncommonly associated with glioma. Cluster analysis from top hub nodes lists several identified glioma-associated gene products to function within protein complexes, including epidermal growth factors as well as cell cycle proteins or RAS proto-oncogenes. -
In This Table Protein Name, Uniprot Code, Gene Name P-Value
Supplementary Table S1: In this table protein name, uniprot code, gene name p-value and Fold change (FC) for each comparison are shown, for 299 of the 301 significantly regulated proteins found in both comparisons (p-value<0.01, fold change (FC) >+/-0.37) ALS versus control and FTLD-U versus control. Two uncharacterized proteins have been excluded from this list Protein name Uniprot Gene name p value FC FTLD-U p value FC ALS FTLD-U ALS Cytochrome b-c1 complex P14927 UQCRB 1.534E-03 -1.591E+00 6.005E-04 -1.639E+00 subunit 7 NADH dehydrogenase O95182 NDUFA7 4.127E-04 -9.471E-01 3.467E-05 -1.643E+00 [ubiquinone] 1 alpha subcomplex subunit 7 NADH dehydrogenase O43678 NDUFA2 3.230E-04 -9.145E-01 2.113E-04 -1.450E+00 [ubiquinone] 1 alpha subcomplex subunit 2 NADH dehydrogenase O43920 NDUFS5 1.769E-04 -8.829E-01 3.235E-05 -1.007E+00 [ubiquinone] iron-sulfur protein 5 ARF GTPase-activating A0A0C4DGN6 GIT1 1.306E-03 -8.810E-01 1.115E-03 -7.228E-01 protein GIT1 Methylglutaconyl-CoA Q13825 AUH 6.097E-04 -7.666E-01 5.619E-06 -1.178E+00 hydratase, mitochondrial ADP/ATP translocase 1 P12235 SLC25A4 6.068E-03 -6.095E-01 3.595E-04 -1.011E+00 MIC J3QTA6 CHCHD6 1.090E-04 -5.913E-01 2.124E-03 -5.948E-01 MIC J3QTA6 CHCHD6 1.090E-04 -5.913E-01 2.124E-03 -5.948E-01 Protein kinase C and casein Q9BY11 PACSIN1 3.837E-03 -5.863E-01 3.680E-06 -1.824E+00 kinase substrate in neurons protein 1 Tubulin polymerization- O94811 TPPP 6.466E-03 -5.755E-01 6.943E-06 -1.169E+00 promoting protein MIC C9JRZ6 CHCHD3 2.912E-02 -6.187E-01 2.195E-03 -9.781E-01 Mitochondrial 2- -
BAC Array CGH in Patients with Velocardiofacial Syndrome-Like
BMC Medical Genetics BioMed Central Research article Open Access BAC array CGH in patients with Velocardiofacial syndrome-like features reveals genomic aberrations on chromosome region 1q21.1 Anna Brunet1,2, Lluís Armengol1, Damià Heine3, Jordi Rosell3, Manel García- Aragonés1, Elisabeth Gabau2, Xavier Estivill*1,4 and Miriam Guitart*2 Address: 1Genes and Disease Program, CIBER en Epidemiología y Salud Pública (CIBERESP), Center for Genomic Regulation (CRG), Barcelona, Catalonia, Spain, 2Genetic laboratory UDIAT-Centre Diagnòstic, Fundació Parc Taulí - Institut Universitari UAB, Corporació Sanitària Parc Taulí, Sabadell, Catalonia, Spain, 3Hospital Universitari Son Dureta, Mallorca, Spain and 4Pompeu Fabra University (UPF), Barcelona, Catalonia, Spain Email: Anna Brunet - [email protected]; Lluís Armengol - [email protected]; Damià Heine - [email protected]; Jordi Rosell - [email protected]; Manel García-Aragonés - [email protected]; Elisabeth Gabau - [email protected]; Xavier Estivill* - [email protected]; Miriam Guitart* - [email protected] * Corresponding authors Published: 23 December 2009 Received: 14 January 2009 Accepted: 23 December 2009 BMC Medical Genetics 2009, 10:144 doi:10.1186/1471-2350-10-144 This article is available from: http://www.biomedcentral.com/1471-2350/10/144 © 2009 Brunet et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Microdeletion of the chromosome 22q11.2 region is the most common genetic aberration among patients with velocardiofacial syndrome (VCFS) but a subset of subjects do not show alterations of this chromosome region. -
Senescence Inhibits the Chaperone Response to Thermal Stress
SUPPLEMENTAL INFORMATION Senescence inhibits the chaperone response to thermal stress Jack Llewellyn1, 2, Venkatesh Mallikarjun1, 2, 3, Ellen Appleton1, 2, Maria Osipova1, 2, Hamish TJ Gilbert1, 2, Stephen M Richardson2, Simon J Hubbard4, 5 and Joe Swift1, 2, 5 (1) Wellcome Centre for Cell-Matrix Research, Oxford Road, Manchester, M13 9PT, UK. (2) Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, M13 9PL, UK. (3) Current address: Department of Biomedical Engineering, University of Virginia, Box 800759, Health System, Charlottesville, VA, 22903, USA. (4) Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, M13 9PL, UK. (5) Correspondence to SJH ([email protected]) or JS ([email protected]). Page 1 of 11 Supplemental Information: Llewellyn et al. Chaperone stress response in senescence CONTENTS Supplemental figures S1 – S5 … … … … … … … … 3 Supplemental table S6 … … … … … … … … 10 Supplemental references … … … … … … … … 11 Page 2 of 11 Supplemental Information: Llewellyn et al. Chaperone stress response in senescence SUPPLEMENTAL FIGURES Figure S1. A EP (passage 3) LP (passage 16) 200 µm 200 µm 1.5 3 B Mass spectrometry proteomics (n = 4) C mRNA (n = 4) D 100k EP 1.0 2 p < 0.0001 p < 0.0001 LP p < 0.0001 p < 0.0001 ) 0.5 1 2 p < 0.0001 p < 0.0001 10k 0.0 0 -0.5 -1 Cell area (µm Cell area fold change vs. EP fold change vs. -
Silencer of Death Domain (BAG4) (NM 004874) Human Recombinant Protein Product Data
OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP306235 Silencer of Death Domain (BAG4) (NM_004874) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Recombinant protein of human BCL2-associated athanogene 4 (BAG4) Species: Human Expression Host: HEK293T Tag: C-Myc/DDK Predicted MW: 49.4 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_004865 Locus ID: 9530 UniProt ID: O95429 RefSeq Size: 4478 Cytogenetics: 8p11.23 RefSeq ORF: 1371 Synonyms: BAG-4; SODD This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 Silencer of Death Domain (BAG4) (NM_004874) Human Recombinant Protein – TP306235 Summary: The protein encoded by this gene is a member of the BAG1-related protein family. BAG1 is an anti-apoptotic protein that functions through interactions with a variety of cell apoptosis and growth related proteins including BCL-2, Raf-protein kinase, steroid hormone receptors, growth factor receptors and members of the heat shock protein 70 kDa family. -
Bcl‑2 Associated Athanogene 4 Promotes Proliferation, Migration and Invasion of Gastric Cancer Cells
MOLECULAR MEDICINE REPORTS 16: 3753-3760, 2017 Bcl‑2 associated athanogene 4 promotes proliferation, migration and invasion of gastric cancer cells LIZHI YI1*, ZHENBING LV2,3*, JIANMEI WANG4 and XIANFEI ZHONG1 1Department of Gastroenterology, Leshan People's Hospital, Leshan, Sichuan 614000; 2Department of General Surgery Two, Nanchong Central Hospital; 3The Second Clinical School of North Sichuan Medical College, Nanchong, Sichuan 637000; 4Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China Received May 22, 2016; Accepted April 4, 2017 DOI: 10.3892/mmr.2017.7073 Abstract. Currently, with the increase of morbidity and the rate of GC mortality has been decreased (4). It is necessary mortality rate, gastric cancer (GC) is attracting increasing to identify the biomarkers that can distinguish between GC attention in China. Bcl-2-associated athanogene 4 (BAG4) patients with poor or good prognosis. has been identified as a tumor promoter in several tumors, Bcl-2 associated athanogene 4 [BAG4, also known as but its role in GC remains unknown. The present study Silencer of Death Domains (SODD)] is a member of the aimed to detect the expression of BAG4 and determine its BAG1‑related protein family (5). The BAG proteins are located function in the progression of GC. The results from reverse in both cytoplasmic and nuclear in cells (6), although the func- transcription‑quantitative polymerase chain reaction and tional importance of this remains unclear. BAG proteins have a western blotting revealed that BAG4 was markedly upregu- conserved BAG domain (BD) that binds to the ATPase domain lated in highly metastatic cell lines (SGC7901 and MGC803), of Hsp70/Hsc70, and regulates the activity of these molecular compared with the lower‑metastatic cell lines (AGS and chaperones (7-9). -
Molecular Markers of Early Parkinson's Disease Based on Gene Expression in Blood
Molecular markers of early Parkinson’s disease based on gene expression in blood Clemens R. Scherzer*†‡§, Aron C. Eklund*, Lee J. Morse*, Zhixiang Liao*, Joseph J. Locascio†, Daniel Fefer*, Michael A. Schwarzschild†‡, Michael G. Schlossmacher*‡, Michael A. Hauser¶, Jeffery M. Vance¶, Lewis R. Sudarsky‡, David G. Standaert†‡, John H. Growdon†‡, Roderick V. Jensenʈ, and Steven R. Gullans* *Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, Cambridge, MA 02139; †Neurology Service, Massachusetts General Hospital, Boston, MA 02114; ‡Partners Parkinson and Movement Disorders Center, Boston, MA 02114; ¶Center for Human Genetics, Duke University Medical Center, Durham, NC 27710; and ʈDepartment of Physics, University of Massachusetts, Boston, MA 02125 Communicated by Gregory A. Petsko, Brandeis University, Waltham, MA, November 24, 2006 (received for review March 12, 2006) Parkinson’s disease (PD) progresses relentlessly and affects five For a biomarker to be clinically useful, noninvasive detection in million people worldwide. Laboratory tests for PD are critically peripheral blood is desirable. The power of this approach for needed for developing treatments designed to slow or prevent identifying disease-associated candidates in a neurodegenerative progression of the disease. We performed a transcriptome-wide disease is precedented by an expression screen of lymphoblasts scan in 105 individuals to interrogate the molecular processes of patients with Alzheimer’s disease (AD), in which we detected perturbed in cellular blood of patients with early-stage PD. The abnormally low signals of the neuronal sorting receptor LR11/ molecular multigene marker here identified is associated with risk SorLa (20). Subsequent analyses of LR11/SorLa’s mechanistic of PD in 66 samples of the training set comprising healthy and role in AD demonstrated that LR11/sorLA modulates APP disease controls [third tertile cross-validated odds ratio of 5.7 (P for trafficking and its processing to amyloid- (21, 22). -
Awakening Guardian Angels: Drugging the P53 Pathway
REVIEWS Awakening guardian angels: drugging the p53 pathway Christopher J. Brown*, Sonia Lain‡, Chandra S. Verma§, Alan R. Fersht|| and David P. Lane* Abstract | Currently, around 11 million people are living with a tumour that contains an inactivating mutation of TP53 (the human gene that encodes p53) and another 11 million have tumours in which the p53 pathway is partially abrogated through the inactivation of other signalling or effector components. The p53 pathway is therefore a prime target for new cancer drug development, and several original approaches to drug discovery that could have wide applications to drug development are being used. In one approach, molecules that activate p53 by blocking protein–protein interactions with MDM2 are in early clinical development. Remarkable progress has also been made in the development of p53-binding molecules that can rescue the function of certain p53 mutants. Finally, cell-based assays are being used to discover compounds that exploit the p53 pathway by either seeking targets and compounds that show synthetic lethality with TP53 mutations or by looking for non-genotoxic activators of the p53 response. Cytotoxic chemotherapy The development of new drugs to treat cancer has under- same time, develop new cancer drugs that will benefit Cell-killing drugs used to treat gone a dramatic renaissance in the past decade, spear- the majority of patients? Progress is highly promising various cancers by targeting headed by the development of both small-molecule and owing to the use of two broad approaches, which are rapidly dividing cells. biological agents that have shown remarkable clinical both well illustrated in the case of p53.